Has Biogen’s Skyclarys (risdiplam) been approved by the FDA?
Biogen’s SKYCLYS/Skyclarys (risdiplam) is an FDA-approved medicine for spinal muscular atrophy (SMA).
What is its FDA approval status going into 2026?
As of the latest available FDA approval information, risdiplam remains FDA-approved; there is no indication in the provided information that its approval has been withdrawn, stayed, or otherwise changed during 2026.
Could the FDA approval status change (withdrawal, label updates, restrictions)?
FDA status can change if the manufacturer stops marketing a product, if safety signals prompt an FDA action, or if new clinical evidence results in label updates. Those kinds of changes would be reflected in FDA communications, but no such change is described in the information provided here.
What patients and caregivers typically look for
People searching “approval status” often want to know whether it is currently eligible for prescription and reimbursement, whether the label has expanded to additional SMA types/ages, and whether there are any current FDA safety communications tied to the product. Those details require the most recent FDA labeling and safety updates, which are not included in the provided information.
What I need to answer precisely for “2026”
Your question is time-specific (“2026”). To confirm the exact current status for 2026 (including any label or safety updates), I need one of the following:
- the exact product name as it appears on the FDA site (SPINRAZA-style spelling issues are common), or
- a link/screenshot to the FDA page you’re referencing, or
- the approval date or application number you want checked.
If you share the FDA link you’re looking at, I can verify the current approval status for 2026 against that page.